Printer Friendly

THE IMMUNE RESPONSE CORPORATION GRANTED EUROPEAN PATENT ON AUTOIMMUNE DISEASE TECHNOLOGY

 CARLSBAD, Calif., Jan. 13 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) today announced that the European Patent Office has granted a Patent entitled Vaccination and Methods Against Diseases Resulting from Pathogenic Responses by Specific T-Cell Populations. The granted Patent, No. EP0463101, relates to autoimmune disease technology developed by the company and claims vaccines and methods for the prevention or treatment of certain autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. The patent names Drs. Mark D. Howell, Steven W. Brostoff and Dennis J. Carlo, as the inventors.
 Immune Response has identified certain T cells, known as autoreactive T cells, that the company believes initiate the attack against normal tissue resulting in the development of certain autoimmune diseases. The goal in developing a treatment for these autoimmune diseases is to block the aberrant T cells while leaving the remainder of the patient's immune system intact.
 The company is conducting two Phase I human clinical trials with a rheumatoid arthritis therapeutic, one based on a VB17 T cell receptor and the second on a VB14 T cell receptor. Both of these therapeutics utilize the technology covered by this issued patent.
 Expanding upon this technology, the company plans to commence, subject to Food and Drug Administration concurrence, a Phase I clinical trial in early 1994 to test a multiple sclerosis therapeutic product.
 "We are extremely pleased that the European Patent Office has confirmed the patentability of our autoimmune disease technology," said Carlo, Ph.D., executive vice president and chief scientific officer. "This patent, along with the previously issued U.S. patents on the company's HIV treatment technology and gene therapy technology, places the company in a very strong competitive position."
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection and autoimmune diseases and, through TargeTech Inc., gene therapy.
 -0- 1/13/94
 /CONTACT: Bronwyn LeMelle or Cindy Rollins, 619-431-7080/
 (IMNR)


CO: Immune Response Corporation ST: California IN: MTC SU:

MF-LS -- SD004 -- 1658 01/13/94 08:00 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1994
Words:338
Previous Article:BWIP HOLDING INC. ANNOUNCES ACQUISITION, RESTRUCTURING PLANS AND LOWER EARNINGS OUTLOOK
Next Article:STUDY FINDS GEN-PROBE'S AMPLIFIED MYCOBACTERIUM TUBERCULOSIS TEST MORE SENSITIVE THAN PCR IN DETECTING M. TUBERCULOSIS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters